GSE62442
Androgen receptor DNA binding in response to different ligands across three prostate cancer cell lines
We performed AR ChIP-seq in LNCaP-AR, VCaP and CWR22PC cells in the presence of vehicle, androgen, or androgen plus antiandrogen. These three cell lines showed variable sensitivity to these drugs. Overall design: To determine the effects of AR agonist (R1881 vs DHT) and antagonists (Bicalutamide vs MDV3100) on the AR cistrome across a panel of prostate cancer cell lines.